The National Institute for Health and Care Excellence (NICE) has recommended to update its Medical Technologies Guidance 36 (MTG36) to reflect changes in the technology from Peristeen® to Peristeen® Plus. Coloplast’s Peristeen® Plus, a medical device for treating constipation and faecal incontinence, follows on from Peristeen®, which was recommended in the original guidance published in 2018. Peristeen® Plus is the only transanal irrigation system that the Medical Technologies Evaluation Programme at NICE has reviewed.
The review of NICE Guidance MTG36 recommends that Peristeen® Plus can be used by a wide range of people, from children to adults, although the patient must receive thorough instructions from a healthcare professional before using this product. Whilst there are currently a number of conservative ways to treat bowel dysfunction for patients who suffer with functional and/or neurological bowel disorders (such as changes to a person’s diet and hydration levels and the use of laxatives and pads), many patients remain symptomatic. The updated guidance will be published next month.
Evidence submitted to NICE showed that used routinely; daily or every other day, Peristeen® Plus is a cost-effective solution to optimise bowel dysfunction and reduce the severity that faecal incontinence and chronic constipation can bring. This gives patients improved quality of life and helps to promote their dignity and independence. The updated NICE Guidance reaffirms that there is a cost-effective solution available for the estimated 1 in 7 adults and 1 in 3 children who suffer from chronic constipation at any one time.
The key recommendations from NICE following its review of Medical Technologies Guidance 36 are therefore to amend the guidance to reflect changes in the technology from Peristeen® to Peristeen® Plus, alongside a revised cost saving for the NHS.
Welcoming the news, Dave Bucher; Campaigns Manager from the Spinal Injuries Association said: “Spinal cord injured people consistently tell us how critically important good bowel management is to them, and I know from my own experience that having improved control of my bowel had a really significant impact on the quality of my life and my mental health. Knowing that NICE has made evidence-based recommendations for the adoption of Peristeen® Plus by the NHS means patients can have complete confidence that there is an effective treatment option available to them. We’re pleased that NICE has recognised the importance of supporting good bowel function and hope this sends a message that people do not need to suffer in silence; support for good bowel management is always available.”
Consultant Gastroenterologist, Dr Ben Disney, University Hospital, Coventry and Warwickshire NHS Trust said: “This is fantastic news for patients and knowing NICE have undertaken this review of Peristeen® Plus is reassuring, as it confirms the clinical and cost-effectiveness of treatments we are recommending. Patients will welcome the news today and it will help many to live a more fulfilled life”.
Clinical Director and Consultant in Spinal Cord Injury, Mr Bakul Soni also added: “This is such positive news for patients. As a health care professional, knowing NICE have undertaken this review of Peristeen® Plus is important when we have limited resources, especially as we try to recover from the Covid pandemic. It’s critical we use clinical and cost-effective treatments and the NICE recommendations published today support our clinical practice.”
Johan Mastrell, Senior Vice President, Coloplast UK & Ireland, said that: “We are really pleased that NICE has reviewed all the clinical evidence again and announced that Peristeen® Plus should be adopted by the NHS, as it did before for Peristeen. We are committed to helping patients with their most intimate healthcare needs and are proud to have the only NICE recommended products in this therapy area; making a real difference for the patients we serve. Patients can be sure that our products demonstrate high quality, whilst also supporting good health outcomes”.
